U.S. First to Receive clariti® 1 day multifocal 3 Add Contact Lenses
Reflecting its steadfast commitment to continuous innovation, CooperVision announced the immediate U.S. availability of its new clariti® 1 day multifocal 3 Add contact lenses. Several of the company’s advanced technologies are combined in the new lens to provide all-day comfort, ease of fit and the widest range, to meet the needs of more patients.*2,3
New Design with CooperVision Binocular Progressive System®
clariti® 1 day multifocal 3 Add features the CooperVision Binocular Progressive System®, an innovative 3 Add design that caters to all levels of presbyopia to provide optimal visual acuity at all distances.4 The design offers the additional advantage of a simplified fitting process to make it easier for practitioners to fit patients with the right lens, without the need for extended chair time.3
High Level of Comfort with Optimized Comfort Edge™ and WetLoc® Technology
With a focus on maximizing patient comfort, CooperVision utilized its proprietary Optimized Comfort Edge™—an upgraded edge design—in the clariti® 1 day multifocal 3 Add contact lens to provide a high level of comfort from the first fit.5,6 The new lens pairs this design with WetLoc® Technology, which creates a naturally wettable lens that locks in moisture to help keep lenses moist throughout the day, supporting all-day comfort.*
“As our R&D teams continuously advance contact lens technology, we actively look for ways to extend meaningful innovations across other products, so that more practices and wearers can benefit,” said Michele Andrews, OD, Vice President, Marketing and Professional & Academic Affairs, Americas, CooperVision. “The addition of the Binocular Progressive System®—the same multifocal design first introduced in the highly regarded MyDay® multifocal—elevates the performance of clariti® 1 day multifocal 3 Add, including the incredible fit success.”
Easy Fits and Refits, Industry-leading Range
In a clinical study, a remarkable 98% of patients were fit with their final clariti® 1 day multifocal 3 Add prescription with two pairs of lenses or fewer.3,7,8
To further enable prescribing for more patients, the new clariti® 1 day multifocal 3 Add is available in the industry-leading range of +8.00D and -12.00D, providing more sphere powers than any other competitive 1-day multifocal lens.2
“A lot of patients who have grown up not requiring any vision correction get to a point in their 40s where they suddenly experience changes in their vision. This is all new to them and can bring on frustration.” said Dr. Michael Shaheen, OD, Hills & Dales Vision, Inc. “Offering solutions like the clariti® 1 day multifocal 3 Add lens gives patients the ability to see without help from glasses, giving them their freedom back.”
It is estimated that 128 million Americans currently have presbyopia, and recent data reveals that 40% of new contact lens wearers are over the age of 40, pointing to substantial opportunity for practices to fit more multifocal contact lenses.9,10
Eye care professionals in the U.S. are first to receive the product, which will be launched in other markets beginning later this year.
Discover more about clariti® 1 day multifocal 3 Add for Your Patients with Presbyopia
For more information, visit clariti® 1 day multifocal 3 Add | CooperVision Practitioner. Also visit CooperVision’s Online Success Center for additional information and learnings about the new clariti® 1 day multifocal 3 Add.
*Manufacturer's quoted core water content.
References:
1. CVI data on file, 2022.
2. CVI data on file 2024. Based on prescription option combinations (sph and add) available across all daily disposable multifocal soft lenses from CVI, JJV, B+L and Alcon in USA Feb 2024.
3. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add; n=90.
4. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add; with ratings from 85 to 89 out of 100; n=90 habitual MFCL wearers.
5. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add with a rating of 88 out of 100; n=90 habitual MFCL wearers.
6. CVI data on file 2021. Prospective, double-masked, bilateral, one-week dispensing study with clariti® 1 day multifocal 3 add; with a rating of 93 out of 100; n=90 habitual MFCL wearers.
7. CVI data on file 2020. Prospective, double-masked, bilateral, one-week dispensing study UK with MyDay® multifocal; n=104 habitual multifocal contact lens wearers.
8. CVI data on file 2021. Prospective, subject-masked, randomized, bilateral, two-week dispensing study at 5 US sites with MyDay® multifocal; n=58 habitual multifocal contact lens wearers.
9. Timothy R. Fricke, MSc. Nina Tahhan, PhD. Serge Resnikoff, MD. Eric Papas. Anthea Burnett. Suit May Ho. Thomas Naduvilath. Kovin S. Naidoo. Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Presbyopia. American Academy of Ophthalmology. Published May 9, 2018.
10. GfK 2024 – All rights reserved, 1/2024.
